Mechanism of β-adrenergic agonist-induced transmural transport of glucose in rat small intestine Regulation of phosphorylation of SGLT1 controls the function by Ishikawa, Yasuko et al.
 .Biochimica et Biophysica Acta 1357 1997 306–318
Mechanism of b-adrenergic agonist-induced transmural transport of
glucose in rat small intestine
Regulation of phosphorylation of SGLT1 controls the function
Yasuko Ishikawa ), Takafumi Eguchi, Hajime Ishida
Department of Pharmacology, Tokushima Uni˝ersity School of Dentistry, Kuramoto-cho, Tokushima 770, Japan
Received 2 July 1996; revised 6 February 1997; accepted 14 March 1997
Abstract
 .The perfusion of rat small intestine with 10 mM epinephrine Epi or 10 mM norepinephrine resulted in significant
w 3 xincreases in the amount of 3-O- methyl- H -D-glucose transported from the mucosal to serosal side. The Epi-induced
increases in glucose transport were coupled with selective increases in b-adrenoceptor density in the mucosal membranes.
Treatment with 0.1 mM okadaic acid increased glucose transport even in the absence of Epi, but that with 1 mM
w  . xstaurosporine or 60 mM N- 2- methylamino ethyl -5-isoquinoline-sulfonamide dihydrochloride completely inhibited the
 .increases in glucose transport induced by 10 mM Epi or 10 mM dibutyryl cAMP. The maximal binding sites B ofmax
w3 x  .H phlorizin in brush border membrane BBM from tissues perfused with Epi was increased, showing increases in the
q  .binding ability of the Na rglucose cotransporter SGLT1 to glucose. Phosphorylation and dephosphorylation of BBM with
 . w3 xprotein kinase A PKA and alkaline phosphatase resulted in increases and decreases in B of H phlorizin, respectively.max
w 32 x 2qThe phosphorylation state of SGLT1 immunoprecipitated from BBM incubated with g- P ATP-Mg and PKA, and the
w32 xanalysis of phosphoamino acids composed of SGLT1 in rats given P orthophosphate indicate the presence of potential
sites for PKA-mediated phosphorylation of SGLT1 at serine. These findings indicate that the regulation of phosphorylation
of SGLT1 leads to an alteration of its function and results in the control of glucose transport in the rat small intestine.
q 1997 Elsevier Science B.V.
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1. Introduction
It has been reported that glucose is transported
across the cell membranes of mammalian tissues by
glucose transporters which have two distinct gene
w xfamilies 1,2 . One is the facilitative glucose trans-
w xporter family, GLUT1–GLUT7 1 , and the other is
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represented by the Naqrglucose cotransporter,
w xSGLT1rSGLT2 2 . Recently, GLUT and SGLT were
shown to be multifunctional proteins, transporting not
w xonly glucose but also water 3,4 .
Transmural transport of glucose from the mucosal
to serosal side of intestine is thought to require at
least two different processes in the epithelial cells:
the sodium-dependent cotransport of glucose carried
 .out by SGLT1 in brush border membrane BBM ,
and facilitated diffusion of glucose via GLUT2 in
w xbasolateral membranes 5,6 . SGLT1 was strongly
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expressed in the apical BBM in the intestine, but
w xSGLT2 was not detected in it 2,5,6 .
 .Epinephrine Epi has been reported to have a
stimulatory effect on glucose transport in rat small
w xintestine 7,8 . It remains to be established, however,
how to transduce the signal from these receptors to
SGLT1 in the small intestine and how to regulate the
function of this transport. It is, therefore, of interest
to investigate the mechanisms of Epi-induced in-
crease in transmural transport of glucose in the rat
small intestine.
It has been found that Epi regulates many kinds of
transporter systems by interacting with a - or b-2
adrenoceptors. Alpha -adrenoceptors are known to be2
linked to the inhibition of adenyl cyclase activity by
w xinteraction with their agonists 9 , whereas b-adren-
oceptors interact with their agonists and activate
adenylate cyclase to produce an increase in cellular
w xcAMP contents 10 . The increases in cAMP content
in the cells lead to an activation of protein kinase A
 .PKA and result in a stimulation of protein phospho-
rylation, culminating in the physiological responses
w x q q11 . The activity of Na rH exchanger from rabbit
renal BBM is inhibited by PKA-mediated phosphory-
w x ylation 12 . The functioning of the Cl channel in
w xapically-located secretory epithelial cells 13 and that
of NaqrKqr2Cly cotransporter in basolateral mem-
w xbranes 14 are stimulated by the phosphorylation of
specific sites on their transporters via PKA. Recently,
attention has been focused on the roles of protein
phosphorylation and dephosphorylation in the control
of the function of transporters.
The present experiments were performed to inves-
tigate the regulatory mechanisms of the function of
SGLT1 by the interaction of Epi with b-adrenocep-
w3 xtors. Binding experiments with H dihydroalprenolol
 .DHA showed that the treatment with Epi increased
the number of b-adrenoceptors in the rat intestinal
mucosa, followed by the stimulation of transmural
transport of glucose. In this regulatory process, the
phosphorylationrdephosphorylation event elicited by
Epi implicated this glucose transport. Our results also
indicated that the potential phosphorylation site for
PKA was recognized in SGLT1 and the binding sites
of SGLT1 to glucose were increased by the increases
in phosphorylation of the sites of SGLT1 in BBM.
These observations indicate that the interaction of Epi
with b-adrenoceptors leads to the phosphorylation of
SGLT1, resulting in an enhancement of the function
of the transporter.
2. Materials and methods
2.1. Animals and diet
 .Male Wistar rats 10 weeks old were used for this
experiment. They were given standard laboratory diet
 .MF, Oriental Yeast, Tokyo, Japan and water ad
libitum, and maintained for at least 2 weeks before
the experiment in a temperature-controlled environ-
 . ment 22"28C with a 12-h lightrdark cycle lights
.on from 6:00 a.m. to 6:00 p.m. . All procedures were
approved by the animal care committee in our univer-
sity.
2.2. Perfusion of intestinal loop and measurement of
the transmural transport of glucose
The rats were killed by a blow on the head and the
abdomen was opened by a midline incision. The
small intestine was cut into a 15-cm loop of jejunum
starting at a point 10 cm below the Ligament of
Treiz, and was then cleaned by flushing with Ringer
solution consisting of 118 mM NaCl, 4.7 mM KCl,
1.2 KH PO , 1.25 mM CaCl , 1.2 mM MgCl and2 4 2 2
24.9 mM NaHCO gassed with a 95% O –5% CO3 2 2
mixture to pH 7.4, as reported previously by Kellet et
w xal. 15 . The loop was cannulated and connected to
the perfusion apparatus with a peristaltic pump. Per-
fusion of the luminal side of the loop with Ringer
solution containing 5 mM glucose and a trace amount
w 3 x w 3 x .of 3-O- methyl- H -D-glucose M- H G was com-
menced immediately at a rate of 1 mlrmin and
continued for 15 min. The perfusate was then changed
to fresh solution with or without the various agents
described in the tables and figures.
The serosal side of the loop was bathed in an
aerated organ bath of a Magnus apparatus filled with
50 ml of Ringer solution containing 5 mM glucose at
378C. Determination of glucose transport activity was
initiated by the addition of various kinds of agents to
the perfusate and was measured by the amount of the
appearance of the radioactivity in serosal medium
using an Aloka liquid scintillation spectrometer
 .model LSC 900 . The amounts of glucose were
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wcaluculated from the specific radioactivity of M-
3 xH G in the perfusate and were expressed as mmol of
glucoserg wet weight of the tissues.
2.3. Preparation of tissue membranes and ˝esicles of
BBM
After the perfusion of the loop of jejunum, mucosa
scraped with a glass slide from the tissue was homog-
enized in 10 vol of buffer-1 containing 50 mM
 .Tris-HCl pH 7.5 and 10 mM MgCl using a glass2
homogenizer with a Teflon pestle followed by cen-
trifugation twice to remove the cell supernatant. The
suspension of the precipitate was filtered through a
 .single layer of Nylon bolting cloth 150 mesh and
centrifuged. The resultant precipitate resuspended in
buffer-1 and used as mucosal membranes.
Vesicles of BBM were also prepared according to
w xthe method of Longbottom et al. 16 . In brief, mu-
cosa obtained as described above was homogenized
in 20 vol of buffer-2 containing 50 mM mannitol,
 .0.25 mM MgCl and 5 mM Hepes pH 7.5 using a2
glass homogenizer with a Teflon pestle, and cen-
trifuged at 300=g for 10 min. The supernatant was
centrifuged at 2000=g for 10 min, and the resultant
supernatant was again centrifuged at 9750=g for 10
min. After the centrifugation of the final supernatant
at 35 000=g for 30 min, the precipitate was sus-
pended in buffer-2, followed by the addition of 1 M
MgCl to a final concentration of 10 mM, and left on2
ice for 30 min. The suspension was centrifuged at
3000=g for 15 min, and the supernatant was again
centrifuged at 35 000=g for 30 min. The resultant
precipitate was washed with 1 mM ethylenediamine
 .tetraacetic acid EDTA by centrifugation to remove
any excess Mg2q. The final pellet was suspended in
buffer-3 containing 100 mM mannitol, 10 mM Hepes
 .pH 7.5 and 100 mM NaSCN, and used as BBM.
2.4. Binding of radiolabeled ligands
b-Adrenoceptors. The final suspension from the
loop mucosa was used for the quantitative measure-
ment of b-adrenoceptors by the method described
w xpreviously 17,18 . The reaction mixtures for the
assay of b-adrenoceptors containing 880 ml of the
 .final suspension 300 mg protein and 100 ml of
w3 xvarious concentrations of H DHA were incubated
for 10 min at 378C with or without 20 ml of 10 mM
propranolol to displace binding of the labeled ligand,
and were then passed through Whatman GFrB filters
and washed three times with 5 ml of ice-cold buffer-1.
SGLT1. The final suspension of vesicles of BBM
was used for the quantitative measurement of SGLT1
w xby the method reported by Gerardi-Laffin et al. 19 .
 .In brief, 100 ml of vesicles of BBM 100 mg protein
were incubated for 2 min at 378C with 100 ml of
w3 xvarious concentrations of H phlorizin in the pres-
ence or absence of 1 mM unlabeled phlorizin. Each
sample was then passed through Whatman GFrF
filters and the filters were washed three times with 5
ml of ice-cold buffer-3.
The radioactivity remaining on the filters was
counted in a vial containing 10 ml of scintillation
w3 x w3 xfluid. The specific H DHA or H phlorizin bind-
ings were expressed as the difference between the
radioactivities in the presence and absence of 10 mM
propranolol or 10 mM phlorizin, respectively. The
 .maximal binding sites B and dissociation con-max
 .stants K were determined by Scatchard analysisd
w x20 and by the method of least squares.
2.5. Phosphorylation and dephosphorylation of BBM
BBM prepared from the loop tissues was used to
phosphorylate or dephosphorylate the BBM proteins
w xas described previously 18,21 . In brief, BBM was
suspended in a medium consisting of 50 mM Tris-HCl
 .buffer pH 7.4 , 10 mM MgCl , 1 mM EDTA, 1 mM2
 . Xdithiothreitol DTT , 1 mM adenosine 5 -triphosphate
 .  .ATP and PKA catalytic subunit 2.5 Urml for 30
min at 258C. For the dephosphorylation of membrane
proteins, the membrane was suspended in a medium
 .consisting of 50 mM Tris-HCl buffer pH 7.4 , 5 mM
MgCl , 1 mM DTT, and alkaline phosphatase AL-2
.  .Pase 1 Urml , followed by incubation for 10 min at
308C. After the termination of the reactions, the
suspension was centrifuged. The resultant precipitate
was washed twice with buffer-3 by centrifugation.
The final precipitate was resuspended in buffer-3 and
w3 xused for H phlorizin binding experiments as de-
scribed above.
2.6. Phosphorylation of SGLT1
To phosphorylate SGLT1, BBM proteins 2 mg
.protein were suspended in buffer-4 containing 10
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w 32 xmM g- P ATP in the presence or absence of PKA
 .catalytic subunit 2.5 Urml for 30 min at 258C. The
reaction was stopped by the addition of trichloro-
 .acetic acid TCA at a final concentration of 6% and
then allowed to stand for 30 min on ice, after which
the proteins were centrifuged at 3000 rpm for 20 min
at 48C. The resulting pellets were washed with ethyl
ether saturated with H O and collected by centrifuga-2
tion. Samples were dissolved, without heating, in
solubilizing buffer consisting of 62.5 mM Tris-HCl
 .  .pH 6.8 , 2% sodium dodecylsulfate SDS , 10%
 .glycerol, 1% 3- 3-cholamidopropyl dimethyl-am-
.  .monio -1-propanesulfonate CHAPS , 5% mercapto-
ethanol and 0.001% bromophenol blue. An aliquots
was subjected to SDS-polyacrylamide gel elec-
 .trophoresis PAGE using a 10% linear polyacryl-
amide gels. After electrophoresis, the gel was exten-
sively washed and the bottom of the gel containing
w 32 xg- P ATP was cut off, and the remainder was then
subjected to autoradiography using Kodak X-Omat
AR film with an intensifying screen at y808C. For
the quantity of the radioactive proteins, the autoradio-
gram was analyzed with a chromatoscanner model
.CS-930, Shimadzu, Japan and the intensity was eval-
uated by measuring the peak areas of absorbance
with an image analyzer.
2.7. Immunoprecipitate and phosphorylation of
SGLT1
 .BBM 10 mg protein was incubated in 2 ml of
w 32 xbuffer-4 containing 10 mM g- P ATP in the pres-
 .ence or absence of PKA catalytic subunit 2.5 Urml
for 30 min at 258C. The reaction was stopped by the
addition of 4 ml of ice-cold buffer-4, followed by
centrifugation at 35 000=g for 30 min. The result-
ing precipitate was solubilized in 1% CHAPS con-
taining buffer-4 consisting of 20 mM Tris-HCl pH
.7.4 , 125 mM NaCl, 1 mM MgCl , 1 mM CaCl , 102 2
mgrml aprotinin and 10 mgrml leupeptin, and stirred
for 30 min at 48C. After centrifugation of the suspen-
sion at 35 000=g for 30 min, the precipitate was
again suspended in 10% CHAPS containing buffer-4
and stirred for 1 h at 48C. The suspension was
centrifuged to remove non-soluble materials. The re-
 .sultant supernatant 5 mg protein was incubated for
12 h at 48C with a 1:20 dilution of polyclonal anti-
SGLT1 antibody against peptide Sawady Technol-
.ogy Co. Ltd., Tokyo corresponding to the cytoplas-
mic loop amino acid residue 604–615: R-A-Y-D-L-
w x.F-C-G-L-D-Q-D 22–24 and applied to a column of
 .Protein A–Sepharose CL-4B 1.5=2.0 cm which
had been equilibrated with 20 mM phosphate buffer
 .pH 7.0 . This antibody was produced by immunizing
rabbits against a synthetic peptide having the same
sequence as the 12 amino acids in the cytoplasmic
loop of SGLT1 as described above. The immune
complex was eluted at the flow rate of 0.2 mlrmin
 .with 10 mM glycine–HCl buffer pH 2.7 . After
dialysis against H O, the eluate was concentrated and2
an aliquot of the sample was dissolved with 1 ml of 1
N NaOH for 30 min at 1008C. A portion of dissolved
sample was used for the measurement of protein by
w xthe method of Lowry et al. 25 . Trichloroacetic acid
 .TCA was added to the remainder at the final con-
centration of 30%. After centrifugated, radioactivity
w xof the phosphate was measured 26 .
2.8. Western blot analysis
BBM was dissolved in the solubilizing buffer de-
 .scribed above. An aliquot 50 mg protein was sub-
jected to SDS-PAGE using a 10% linear polyacryl-
amide gel. After electrophoresis, the proteins were
electrophoretically transferred from the unstained gel
to nitrocellulose transfer membranes Hybond ECL,
.Amersham, Buckinghamshire, UK in a transfer
 .buffer containing 25 mM Tris-HCl buffer pH 8.3 ,
192 mM glycine and 20% methanol for 30 min at 15
V using a Trans-Blot apparatus Bio-Rad, Hercules,
.CA, USA . Blots were incubated with anti-SGLT1
 .antibody 1:1000 for 1 h. Then, anti-SGLT1 anti-
body was detected by the ECL chemiluminescense
 .method Amersham .
2.9. Separation of phosphohydroxyamino acid con-
sisting of SGLT1
Intestinal loops were obtained from rats which had
w 32 x been injected with P orthophosphate 15.8
.TBqr100 g body weight intraperitoneally 1 h before
experiments. After perfusion with or without Epi, the
intestinal loop was used to prepare BBM as described
above. The materials solubilized by CHAPS at con-
centrations between 1 and 10% in buffer-4 were
incubated with anti-SGLT1 antibody to precipitate
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immunologically SGLT1. The immunocomplex was
collected by using a Protein A–Sepharose CL-4B
column as described above. After dialysis against
H O, the eluate was concentrated. Aliquots of the2
sample were hydrolyzed in 4 N HCl at 1108C for 3 h
w x27 . After evaporation to dryness, the hydrolysate
was dissolved in 10 mM potassium phosphate buffer
 .pH 3.0 containing 12.5% methanol, and an aliquot
of it was injected onto a QAE-2SW column TSKgel,
.4.6 mm=25 cm . Elution was performed with potas-
sium phosphate–methanol buffer at a flow rate of 0.5
mlrmin. One-milliliter fractions were collected and
analyzed for the radioactivity and the relative ab-
 .sorbance at 205 nm. O-phospho-DL-serine P-Ser ,
 .O-phospho-DL-threonine P-Thr and O-phospho-DL-
 .tyrosine P-Tyr were also used to identify phospho-
amino acids in the hydrolysate.
2.10. Statistical analyses
All values given are the mean"S.E. for a group
of animals. The number of animals used for each
variable is given in the tables and figures. The statis-
tical values of differences between means was deter-
mined by the unpaired Student’s t-test. A significant
difference between the means of two samples was
defined as P-0.05.
2.11. Materials
w 3 x  . w 32 xM- H G 2.22–3.33 TBqrmmol , g- P ATP
 . w32 x 111 TBqrmmol and P orthophosphate 315–337
.TBqrmmol were obtained from DuPontrNew Eng-
 .land Nuclear Wilmington, DE, USA . PKA catalytic
subunit, ALPase and staurosporine were purchased
 . wfrom Sigma St. Louis, MO, USA . N- 2-methyl-
. xamino ethyl -5- isoquinoline-sulfonamide dihydro-
 .chloride H-8 was from BIOMOL Research Labora-
tories, Inc. CHAPS and EDTA were purchased from
 .Dojindo Laboratories Kumamoto, Japan . Okadaic
acid was from Wako Pure Chemical Industry, Ltd.
 .  .Osaka, Japan . Epi and norepinephrine Nor were
from Mann Research Laboratories New York, NY,
.USA and Aldrich Chemical Company Inc.
 .Milwaukee, WI, USA , respectively.
3. Results
3.1. Effects of Epi and Nor on glucose transport in
rat small intestine
The addition of 1 mM Epi or 1 mM Nor to the
perfusate of the mucosal side of the loop of rat small
w 3 xintestine markedly increased the amount of M- H G
 .transported to the serosal side Fig. 1 . The amounts
of Epi- or Nor-induced glucose transport increased in
a dose-dependent manner, reaching a maximum at the
concentration of 50 mM of each catecholamine. The
EC values for Epi and Nor, calculated from the50
amounts of glucose transported for 30 min, were 0.63
and 0.85 mM, respectively, indicating that the sensi-
tivity of the tissues to Epi was higher than that to
Nor. As shown in Table 1, IPR and procaterol had
Fig. 1. Concentration–response curve of transmural transport of
glucose in rat small intestine perfused with Epi and Nor. Rat
intestinal loop equilibrated with Ringer solution containing 5 mM
w 3 xglucose and a trace amount of M- H G were perfused for 30 min
 .without ‘ or with the solution containing the indicated concen-
 .  .trations of Epi v or Nor ’ . The amounts of glucose trans-
ported from the mucosal to serosal side were determined as
described in Section 2.2. Inset: Transmural transport of glucose
in small intestine perfused with 10 mM Epi or 10 mM Nor for 30
 .  .min hatched and 60 min open . Each point represents the mean
of four to eight experiments. The range of values obtained is
shown. Significantly different from the the value obtained with-
 . ) ))out C catecholamines at P -0.01, P -0.05.
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Table 1
Effects of adrenergic and cholinergic agonists on transmural
transport of glucose in rat small intestine
Addition Glucose transported
 .  .mM mmolrg wet weight
None 25.5"3.5
 .Acetylcholine 10 26.7"2.0
) .Epinephrine 10 87.0"5.6
) .Norepinephrine 0 69.0"0.1
)) .Isoproterenol 10 54.6"2.9
 .Dobutamine 10 30.7"0.9
)) .Procaterol 10 55.1"2.1
After perfusion for 15 min with Ringer solution containing 5 mM
w 3 xglucose and a trace amount of M- H G, rat small intestinal loops
were treated with the indicated agonists for 30 min. Radioactivi-
ties in the serosal solution were determined as described in
 .Section 2.2. Values are means"S.E. ns4–8 . Significantly
different from the control value at ) P -0.01, )) P -0.05.
also the same stimulatory effects on the glucose
transport in the tissues, but dobutamine did not. The
increase in the amount of glucose transported by Epi
was completely inhibited by propranolol or butoxam-
ine, but not by yohimbine, prazosin or atenolol at the
 .concentration of 100 mM Table 2 . In contrast, 10
mM acetylcholine had no effect on glucose transport
 .in the tissues Table 1 . These results indicate that the
glucose transport induced by Epi or Nor in rat small
intestine is mediated through b -adrenoceptors in the2
tissues.
3.2. Effect of Epi on b-adrenoceptors in mucosal
membranes
Membranes prepared from the mucosa scraped
from rat small intestine which had been perfused with
or without 10 mM Epi for 30 min were used for the
quantitative measurement of b-adrenoceptors. The
w3 xb-adrenergic antagonist H DHA bound specifically
to the membrane, and the binding became saturated
w3 x with increase in the concentration of H DHA Fig.
.2A . A Scatchard plot gave a single straight line,
indicating a single population of binding sites Fig.
.2B . After perfusion of the small intestine with 10
mM Epi for 30 min, the tissue membrane showed
w3 xsignificant increases in the binding ability to H DHA
 .Fig. 2A and B . As illustrated in the inset of Fig. 2B,
the data obtained from the experiments in Fig. 2 and
four other separate experiments indicated that Bmax
values increased from 80.2"7.7 to 158.0"11.8
fmolrmg protein with little change in the K valuesd
4.3"0.3 nM in the control tissues, 5.0"0.4 nM in
.the tissues perfused with Epi .
3.3. Effects of staurosporine, H-8 and okadaic acid
on transmural transport of glucose
The addition of 10 mM dibutyryl cAMP to the
perfusate stimulated 4-fold the amount of glucose
transported for 30 min as compared with that in the
 .absence of dibutyryl cAMP Table 3 . This result
shows that the cAMP contents increased by the inter-
action of b-adrenoceptors with Epi have a stimula-
tory effect on the transmural transport of glucose in
rat small intestine.
Table 2
Effects of adrenergic antagonists on transmural transport of glu-
cose stimulated by epinephrine in rat small intestine
Addition Glucose transported
 .  .mM mmolrg wet weight
 .A None 25.5"3.5
) .Epinephrine 10 87.0"5.6
 .Propranolol 100 25.0"1.8
 .  .Propranolol 100 qepinephrine 10 29.8"1.5
 .Atenolol 100 24.8"0.3
) .  .Atenolol 100 qepinephrine 10 76.0"3.4
 .Butoxamine 100 25.8"1.0
 .  .Butoxamine 100 qepinephrine 10 27.2"2.6
 .Yohimbine 100 28.7"1.5
) .  .Yohimbine 100 qepinephrine 10 83.2"4.6
 .B None 25.2"2.1
) .Epinephrine 10 83.7"10.2
 .Prazosin 100 21.0"3.3
) .  .Prazosin 100 qepinephrine 10 80.6"7.9
 .A Rat intestinal loops equilibrated with Ringer solution contain-
w 3 xing 5 mM glucose and a trace amount of M- H G were perfused
for 15 min with or without the indicated adrenergic antagonists
and then in the presence or absence of epinephrine for 30 min.
Radioactivities in the serosal solution were determined as de-
 .scribed in Section 2.2. Values are means"S.E. ns4–8 .
 .  .B In this experiment, Tris-HCl buffer pH 7.4 was used instead
of NaHCO in Ringer solution. Rat intestinal loops equilibrated3
with the solution described above were perfused for 15 min with
or without prazosin. The perfusion was then continued in the
presence or absence of Epi for 30 min. Radioactivities in the
serosal solution were determined as described in Section 2.2.
 .Values are means"S.E. ns4–6 . Significantly different from
the control value at ) P -0.01.
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w3 x  .  .Fig. 2. Effect of Epi on H DHA binding in intestinal mucosa. Rat intestinal loop was perfused with v or without ‘ 10 mM Epi for
30 min. The mucosal membrane obtained as described in Section 2.2 was incubated in the presence of various concentrations of
w3 xradiolabeled ligand. The amount of specifically bound H DHA was determined using 0.2 mM propranolol to estimate nonspecific
binding. A, saturation curves. B, Scatchard plot of data in A. In this experiment, which represents a typical pattern, B values weremax
 .  .  .87.9 ‘ and 145.3 v fmolrmg protein. Inset: B and K values the mean values of five experiments"S.D. . The B valuesmax d max
significantly different from the value obtained from the tissues treated without Epi; P-0.01.
To determine whether the effect of cAMP on the
glucose transport is mediated by PKA and whether
the stimulatory effects of Epi and cAMP are regu-
lated by protein kinase and protein phosphatase, the
intestinal loops which had been pretreated with 1 mM
Table 3
Effects of staurosporine and okadaic acid on transmural transport
of glucose in rat small intestine stimulated by epinephrine or
dibutyryl cAMP
Addition Glucose transported
 .  .mM mmolrg wet weight
None 21.0"0.6
) .Epinephrine 10 83.5"3.8
) .Dibutyryl cAMP 10 89.6"7.1
 .Staurosporine 1 21.3"2.1
 .  .Staurosporine 1 q epineprine 10 28.5"1.9
 .  .Staurosporine 1 qdibutyryl cAMP 10 38.7"1.4
 .H-8 60 27.8"3.9
 .  .H-8 60 qepinephrine 10 29.8"0.5
) .Okadaic acid 0.1 78.3"1.3
) ..  .Okadaic acid 0.1 qepinephrine 10 113.5"1.1
Rat intestinal loops equilibrated with Ringer solution containing
w 3 x5 mM glucose and trace amount of M- H G were perfused for
15 min with or without staurosporine, H-8 or okadaic acid at the
concentrations indicated. The perfusion was then continued for
30 min in the presence or absence of epinephrine or dibutyryl
cAMP. Radioactivities in the serosal solution were determined as
 .described in Section 2.2. Values are means"S.E. ns4 . Signif-
icantly different from the respective control value at ) P -0.01.
staurosporine, 60 mM H-8 or 0.1 mM okadaic acid
for 30 min were then perfused with medium contain-
ing 10 mM Epi or 10 mM dibutyryl cAMP with 1
mM staurosporine, 60 mM H-8 or 0.1 mM okadaic
acid. As shown in Table 3, staurosporine and H-8,
w xwhich are known as a general PK inhibitor 28 and a
w xhighly specific PKA inhibitor 29 , respectively, com-
pletely abolished the glucose transport induced by
Epi or dibutyryl cAMP, but had no effect on glucose
transport in the absence of these agents. In contrast,
pretreatment of okadaic acid at the concentration of
0.1 mM which inhibited protein phosphatase 1 and
w x2A 21 , markedly increased the amount of glucose
transported in spite of the absence of 10 mM Epi, in
comparison with that of the tissues which had not
been pretreated with 0.1 mM okadaic acid. The addi-
tion of 10 mM Epi together with 0.1 mM okadaic
acid significantly enhanced the glucose transport in-
 .duced by 10 mM Epi Table 3 .
These results indicate that phosphorylation events
elicited by PKA play an important role in the regula-
tion of Epi-induced transmural transport of glucose in
the rat small intestine.
3.4. Effects of phlorizin, ˝inblastine and ouabain on
transmural transport of glucose
Intestinal loops which had been pretreated with
100 mM phlorizin, 100 mM ouabain or 10 mM
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Table 4
Effects of phlorizin, ouabain and vinblastine on transmural trans-
port of glucose in rat small intestine stimulated by epinephrine
Addition Glucose transported
 .  .mM mmolrg wet weight
None 24.4"3.5
) .Epinephrine 10 83.2"5.6
 .Phlorizin 100 20.1"0.9
 .  .Phlorizin 100 qepinephrine 10 24.7"1.8
 .Ouabain 100 20.8"0.8
 .  .Ouabain 100 qepinephrine 10 21.0"4.6
 .Vinblastine 10 15.2"1.2
 .  .Vinblastine 10 qepinephrine 10 17.0"0.9
Rat intestinal loops, equilibrated with Ringer solution containing
w 3 x5 mM glucose and trace amount of M- H G, were perfused for
15 min with or without phlorizin, ouabain or vinblastine at the
concentrations indicated in the table. The perfusion was then
continued for 30 min in the presence or absence of epinephrine.
Glucose contents in the serosal solution were detected as de-
 .cribed in Section 2.2. Values are means"S.E. ns4 . Signifi-
cantly different from the control value at ) P -0.01.
vinblastine for 15 min were perfused with 10 mM
Epi. Phlorizin, which is known to bound to SGLT1
with great affinity and to potently inhibit the active
w xtransport of glucose in BBM 30,31 , caused com-
plete abolishment of glucose transport induced by
Epi. Vinblastin and ouabain completely inhibited the
 .Epi-induced glucose transport Table 4 . These find-
ings show that glucose is transported through the
transcellular route from the mucosal to serosal side in
the intestine perfused with Epi.
3.5. Effect of Epi on phlorizin binding and concentra-
tion of SGLT1 in BBM
w3 xBinding experiments with H phlorizin showed
that radiolabeled ligands bound specifically to BBM
prepared from mucosa after perfusion with or without
10 mM Epi. The binding became saturated with
w3 x increase in the concentration of H phlorizin Fig.
.3A . A Scatchard plot gave a single straight line,
indicating a single population of binding sites Fig.
.3B . After treatment with Epi for 30 min, the Bmax
w3 xvalue of BBM to H phlorizin increased from 18.3
"2.0 to 28.4"3.7 pmolrmg protein, with little
 .change in the K value Fig. 3, inset .d
The concentration of SGLT1 in BBM was assessed
 .by Western blotting Fig. 4 . Anti-SGLT1 antibody
specifically recognized this protein. The immuno-
reactivity in BBM prepared from intestine perfused
w3 x  .  .Fig. 3. Effect of Epi on H phlorizin binding in BBM. Rat intestinal loop was perfused with v or without ‘ 10 mM Epi for 30 min.
After perfusion, BBM prepared as described in Section 2.3 was incubated in the presence of various concentrations of radiolabeled ligand.
w3 xThe amount of specifically bound H phlorizin was determined by using 1 mM unlabeled phlorizin to estimate nonspecific binding. A,
 .saturation curves. B, Scatchard plot of data in A. In this experiment, which represents a typical pattern, B values were 18.2 ‘ andmax
 .  .32.5 v pmolrmg protein. Inset: B and K values the mean of four experiments"S.D. . The B values significantly differentmax d max
from the value obtained from the tissues treated without Epi; P-0.01.
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Fig. 4. Western blot analysis of BBM. Rat intestinal loops were
 .  .perfused with E or without C Epi for 30 min. After perfusion,
BBM prepared as described in Section 2.3 was dissolved in
solubilized buffer. After electrophoresis in SDS-PAGE, samples
were transferred to a nitrocellulose membrane and probed with
anti-SGLT1 antibody. This blot was visualized with ECL. Similar
results were observed in two other experiments.
with Epi for 30 min was clearly detected, in compari-
son with that in BBM from intestine perfused without
Epi.
These findings show that the number of binding
sites of SGLT1 to glucose in BBM increased by the
treatment of the tissue with Epi and was associated
with the increases of the localization of SGLT1 in
BBM.
3.6. Effect of treatment of BBM with PKA or ALPase
on phlorizin binding
BBM treated with PKA catalytic subunit 2.5
.Urml in the presence of 10 mM ATP and 10 mM
 .MgCl or with ALPase 1 Urml to phosphorylate or2
dephosphorylate the membrane proteins, respectively,
were used for the binding experiments with
w3 xH phlorizin. Treatment with ALPase showed that
the B value decreased from 19.2"1.3 to 14.6"max
0.6 pmolrmg protein, with little change in the Kd
values 7.6"0.7 mM in the control tissues, 7.2"0.8
.  .mM in ALPase-treated tissues Fig. 5, inset . In
contrast, treatment with PKA catalytic subunit in-
creased the B values from 19.2"1.3 to 22.3"1.2max
pmolrmg protein, with little change in the K valuesd
 .  .7.4"0.7 mM in PKA-treated tissues Fig. 5, inset .
w xIt was suggested by Torchia et al. 32 that the
phosphorylation of the NaqrKqr2Cly cotransporter
could result in an increase in the overall activity of
the cotransporter by either increasing the affinity of
the protein for transporting ions, or through a confor-
mational change increasing the turnover of the trans-
porter. It seems that the phosphorylation state of
SGLT1 did not affect the affinity of SGLT1 for
transporting glucose. Despite the exclusion of cellular
components during the membrane preparation, treat-
ment with the PKA of BBM produced an increase in
w3 xthe B values of H phlorizin, suggesting that themax
phosphorylation of SGLT1 resulted in conformational
changes of this transporter. In contrast, the treatment
of BBM with ALPase seemed to result in the confor-
w3 xFig. 5. Effects of the treatment of BBM with PKA catalytic subunit or ALPase on H phlorizin binding. BBM prepared from rat small
 .  .  .intestine was treated without ‘ or with PKA catalytic subunit 2.5 Urml, v or ALPase 1 Urml, ^ . BBM was prepared as
described in Section 2.3. A, saturation curves. B, Scatchard plot of data in A. In this experiment, which represents a typical pattern, Bmax
 .  .  .  .values were 23.5 v , 19.8 ‘ and 15.2 ^ pmolrmg protein. Inset: B and K values the mean values of four experiments"S.D. .max d
The B values in PKA catalytic subunit-treated BBM significantly different from the value obtained from the tissues treated withmax
ALPase; P-0.01.
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Fig. 6. The stoichiometry of phosphorylated SGLT1 by PKA
w 32 xcatalitic subunit. BBM was incubated with g- P ATP and
 .  .MgCl in the presence B or absence A of 2.5 Urml of PKA2
catalytic subunit for 30 min at 258C. After SDS-PAGE, the gel
 .was autoradiographed I . The intensity of radiolabeled phospho-
 .protein is presented II . The arrows indicate the position of 78
kDa.
mational change andror internalization of SGLT1.
These findings show that the regulation of the phos-
phorylation state of SGLT1 is of importance in the
control of the function of this transporter.
3.7. Determination of the stoichiometry of phosphory-
lated SGLT1 by PKA
To determine the presence of phosphorylation sites
on SGLT1, BBM were incubated with PKA catalytic
w 32 xsubunit in the presence of g- P ATP and MgCl .2
After SDS-PAGE of phosphorylated membrane pro-
teins, the autoradiogram of the gel showed that 32P
was potently detected on a protein band with the
 .molecular mass of 78 kDa, namely SGLT1 Fig. 6 .
The intensity of the radioactivity associated with the
band was stronger in the sample incubated with PKA
than in the sample without the enzyme.
Immunoprecipitates with anti-SGLT1 from BBM
incubated with PKA catalytic subunit in the presence
w 32 x 32of g- P ATP and MgCl showed that P was2
w 32 xincorporated rapidly and strongly from g- P ATP
 32into the immunocomplex incorporated P; 2225"
80 cpmrmg protein in non-treated BBM, 5766"242
.cpmrmg protein in PKA-treated BBM .
These results show the presence of the sites for
PKA-mediated phosphorylation on SGLT1 in BBM.
w32 xFig. 7. Typical elution profile of hydrolysis of phosphorylated SGLT1 by FPLC. P Orthophosphate was injected into rats
 .  .intraperitoneally 1 h prior to the experiment. The intestinal loop was perfused with v or without ‘ 10 mM Epi for 30 min. The
SGLT1 was immunoprecipitated with anti-SGLT1 antibody and then hydrolized in 4 N HCl at 1108C for 3 h. The dried hydrolysate was
 .dissolved in potassium phosphate–methanol buffer pH 3.0 , and aliquots of samples were injected onto a QAE-2SW column. The
phosphoamino acids were eluted at the flow rate of 0.5 mlrmin. The results represent the radioactivity present in 1 ml of each fraction.
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3.8. Separation of phosphoamino acids in the phos-
phorylated SGLT1
The intestinal loops prepared from the rats which
w32 xhad been injected P orthophosphate were perfused
with or without Epi. The immunoprecipitates with
anti-SGLT1 antibody were obtained from the BBM
prepared from perfused loops and were then hydro-
lyzed with 4 N HCl. The elution profile of the
hydrolysate of the phosphorylated immunoprecipi-
tates indicated that the radiolabeled phosphoamino
acids which had been clearly detected were P-Thr
and P-Ser. The radioactivity of P-Tyr was not de-
tected clearly. The highest radioactivity in these
phosphoamino acids was detected in P-Ser. Incorpo-
rations of the radioactivity into P-Ser were signifi-
cantly enhanced in the immunoprecipitates with anti-
SGLT1 antibody of the loop which had been perfused
 .with Epi Fig. 7 . These results indicate that serine
residues on SGLT1 are potently phosphorylated by
the interaction of Epi with the b -adrenoceptors in2
intestinal mucosa.
4. Discussion
w xIt was reported by Aulsebrook 7 that Epi and Nor
had a stimulatory effect on transmural transport of
glucose in rat small intestine. In the present study, we
confirmed that the interaction of Epi or Nor with
b -adrenoceptors induced the stimulation of transmu-2
ral transport of glucose in rat small intestine Tables
.1 and 2 .
It is well known that the intestinal mucosa is
extensively innervated by adrenergic fibers and that
high levels of Nor can potentially be achieved at the
w xvicinity of the epithelial cells 33,34 . Alpha -adren-2
oceptors were reported to be detected in the intestinal
mucosa, and the interaction of adrenergic agonists
with a -adrenoceptors augmented the net absorption2
of sodium and chloride ions from the intestinal lumen
w x35,36 . However, the existence of b-adrenoceptors
and their function in the intestinal mucosa have not
w3 xbeen established. We observed that H DHA bound
specifically to mucosal membranes of rat small intes-
tine, and the B values markedly increased in themax
tissues after perfusion with Epi with little change in
 .K values Fig. 2 .d
The b-agonists perfused into the luminal side of
the intestinal loop are passed through the transcellular
route and then interact with the b -adrenoceptors2
located in the basolateral membrane of epithelial
cells. The biogenic amine transporter has been identi-
w xfied in epithelial cells 37 . This transporter is most
likely responsible for catalyzing the transport of Epi
and Nor. There are little available data concerning
whether this transporter participates in the transport
of IPR and procaterol. As shown in Table 1, the
amount of transmural transport of glucose in the
small intestine in response to Epi was greater than
that to IPR or procaterol at the same concentration.
This phenomenon might be a reflection of the differ-
ences in the absorption rates among these drugs.
Phlorizin is reported to have a great affinity for
SGLT1, but not for GLUT2, and inhibits the function
w xof SGLT1 30,31,38 . These reports support our find-
w3 xings that 0.5–8.0 mM H phlorizin bound specifi-
 .cally to BBM of intestinal mucosa Fig. 3 and the
Epi-induced stimulation of glucose transport was in-
 .hibited by phlorizin Table 4 . B values formax
w3 xH phlorizin were increased in BBM prepared from
 .intestine which had been perfused with Epi Fig. 3 ,
indicating that Epi increased the binding sites of
SGLT1 to glucose in BBM. By Western blotting, the
increased amount of SGLT1 was recognized in BBM
that responded to Epi. The enhancement of the func-
tion of SGLT1 in the intestine stimulated by Epi
appears to be due to the increase in the amounts of
SGLT1 itself distributed in BBM.
Dibutyryl cAMP also stimulated the transmural
 .transport of glucose Table 3 , suggesting that the
stimulatory effect of Epi is mediated by cAMP which
content is increased in the mucosa. Staurosporine and
H-8 strongly inhibited transmural transport of glucose
 .by Epi or dibutyryl cAMP Table 3 . Okadaic acid,
alone or in the combination with Epi, stimulated the
transmural transport of glucose. The importance of
phosphorylation in this process was also confirmed
by the finding that phlorizin binding abilities in BBM
which had been treated with PKA catalytic subunit or
ALPase increased and decreased, respectively Fig.
.4 . These findings suggest that Epi stimulates the
transmural transport of glucose by increasing the
number of binding sites of SGLT1 to glucose via the
phosphorylation event mediated by PKA in BBM.
Wright proposed that the sites of phosphorylation
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of SGLT1 were Ser-303 and -418, judging from the
w xsequence of SGLT1 that he determined 5 . As shown
in Fig. 6, potent phosphorylation sites were present at
serine residues on SGLT1. This finding was sup-
ported by the result that the immunoprecipitate was
potently phosphorylated by PKA catalytic subunit.
w xLytle and Forbush 39 have shown that
NaqrKqr2Cly cotransport is regulated by direct
reversible phosphorylation at the serine and threonine
sites in secretory epithelia in response to cAMP-de-
pendent stimuli or cell shrinkage. Furthermore, their
group showed that the actual number of
NaqrKqr2Cly cotransporters in basolateral mem-
brane may be altered such that stimulation could
involve the actual translocation of the transport pro-
tein from an intracellular store to basolateral mem-
w xbrane 32,39 . Many kinds of transporters translocate
from intracellular stores to plasma membranes by
w xincreasing their rate of exocytosis 12 . There is much
debate as to whether the phosphorylationrdephos-
phorylation of a transporter itself regulates its translo-
cation in the present study. The enhancement of the
w3 xB values of H phlorizin in BBM treated withmax
PKA in the present study was only slight, because of
the exclusion of cellular components during the
 .membrane preparation Fig. 5 . In contrast, the Bmax
w3 xvalues of H phlorizin in BBM treated with ALPase
were reduced to 60% of those in PKA-treated BBM,
suggesting that the dephosphorylation of SGLT1 in-
duces an internalization of SGLT1. Bradbury et al.
w x40 proposed that dephosphorylation of the apically-
located secretory epithelial Cly channel would lead
to an increase in the binding of adaptor protein and
hence to an increase in the exocytosis of this trans-
porter. Since it is still unclear as to whether dephos-
phorylated SGLT1 bound to adaptor protein, further
experiments are necessary to clarify this mechanism.
In any case, it seems that the phosphorylationrde-
phosphorylation of is SGLT1 involved in the cycling
of the cotransport protein between intracellular stores
to the BBM.
Herein we demonstrated that the interaction of
b-adrenoceptors with b-agonists in rat small intestine
induced phosphorylation of SGLT1 via PKA activa-
tion and led to the enhancement of the function of
this transporter, resulting in an increase in glucose
transport in the small intestine.
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